Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Rallybio Corp has a consensus price target of $8.3 based on the ratings of 6 analysts. The high is $15 issued by Evercore ISI Group on December 21, 2023. The low is $1.5 issued by Jefferies on February 7, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and JMP Securities on August 12, 2024, May 10, 2024, and April 19, 2024, respectively. With an average price target of $7.67 between HC Wainwright & Co., HC Wainwright & Co., and JMP Securities, there's an implied 578.47% upside for Rallybio Corp from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Rallybio (NASDAQ:RLYB) was reported by HC Wainwright & Co. on August 12, 2024. The analyst firm set a price target for $6.00 expecting RLYB to rise to within 12 months (a possible 430.97% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for Rallybio (NASDAQ:RLYB) was provided by HC Wainwright & Co., and Rallybio maintained their buy rating.
There is no last upgrade for Rallybio
The last downgrade for Rallybio Corp happened on May 15, 2024 when JP Morgan changed their price target from N/A to N/A for Rallybio Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rallybio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rallybio was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.
While ratings are subjective and will change, the latest Rallybio (RLYB) rating was a maintained with a price target of $9.00 to $6.00. The current price Rallybio (RLYB) is trading at is $1.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.